Baricitinib (Olumiant®) for atopic dermatitis. HTA ID: 21050

Assessment Status Rapid Review complete
HTA ID 21050
Drug Baricitinib
Brand Olumiant®
Indication Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 09/11/2021
Rapid review completed 16/12/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.